3 Stocks for Investors Who Still Believe Cash Is King

As summer winds down, investors are still climbing the stock market's wall of worry. On the one hand, solid reports from companies like Microsoft (NASDAQ: MSFT), Salesforce (NYSE: CRM), and NVIDIA (NASDAQ: NVDA) show the artificial intelligence trade has room to run.

But there's more than enough evidence to cause investors to rethink their portfolios. Consumer confidence remains at recession-like levels. Some of that is due to the continued creep of higher prices and an interest rate policy that isn't stimulative.

But just because investors are willing to look through inflation and interest rates doesn't mean they're not taking safety precautions. There's been a noticeable shift towards solid dividend-paying companies. That's because when investors start to worry, they take shelter in cash.  It's a reminder that generating reliable income from dividends can be an effective hedge against volatility.

Why Cash Is Becoming King in 2026

The gap between the AI trade's headline valuations and the rest of the market is exactly the kind of perception-versus-fundamentals split that tends to send investors looking for shelter. When a handful of mega-cap names carry most of an index's gains, the reward for chasing them starts to feel smaller than the risk of being wrong. Dividend payers offer a different value proposition entirely: cash that shows up whether or not sentiment cooperates.

That shift isn't just anecdotal. Flows into dividend-focused ETFs have picked up in 2026, and the stocks being rewarded have the balance sheets and payout discipline to keep writing checks in a choppy rate environment. For investors, that means income becomes a hedge against being wrong about the macro picture, not just a return on capital.

The three names below approach that discipline differently: one is rebuilding investor trust after a painful cut, another is running a formal capital-return policy tied to free cash flow, and the third is being priced as if its best days are behind it. Each tells a different story about what "cash is king" means in practice.

AT&T: Reminding Investors Why It's Still Worth a Look

AT&T (NYSE: T) was considered dividend royalty before cutting its dividend in 2022 as part of its WarnerMedia spinoff. The company had accumulated over $180 billion in debt, stretching the payout ratio for the existing dividend to over 60%.

That left a bad taste in the mouths of many investors who relied on the dividend for income. But a cut is not the same as a suspension, and AT&T has maintained its current dividend, which yields about 4.3%. More importantly, that dividend has a payout ratio of around 36%, meaning there's a margin of safety that was one of the goals behind the cut.

That security aligns well with investors who value the company's stable, essential business model. AT&T is delivering year-over-year growth in revenue and earnings and recently announced a $10 billion share buyback program to go along with that dividend.

ONEOK: A Formal Policy for Returning Cash

Energy stocks, particularly those in the oil and gas industry, have delivered market-beating performance in 2026. ONEOK (NYSE: OKE) is up 30% this year but has more room to run.

The company operates in the midstream sector with its network of natural gas and natural gas liquid (NGL) pipelines. In its Q2 2026 earnings report, it raised its full-year guidance for the second time. That came even as the company forecasted a decline in natural gas earnings in the second half of the year as additional capacity comes online.

But OKE stands out to income investors for its stated policy of distributing 75%-85% of its free cash flow (FCF) to shareholders through dividends and buybacks. The dividend currently yields 4.5% and pays $4.28 per share annually.

Pfizer: A Contested Value Play in Healthcare

Pfizer Inc. (NYSE: PFE) has been a polarizing stock for investors. Income investors love the company's dividend, which has the best yield of the three stocks in this group at 6.1% as of this writing.

However, critics of PFE say the yield is a trap that masks the company's slowing growth since its meteoric rise from its Covid-19 vaccine. The company has an extensive pipeline, particularly in the growing area of personalized medicine. The payoff, however, is still years away.

That said, the stock is trading roughly 15% below what could be considered a fair value estimate based on expected earnings growth. Plus, healthcare is becoming a go-to sector for investors looking for an alternative to the AI trade.

Companies Mentioned in This Article: